GlassScriptPhysician profile
Andrea G Mabry
NPI 1366709255
$12,175.64
in general payments reported to CMS, 2019-2025
37 companies · $1,934 in 2025
The $1,934 reported for 2025 was more than what 75% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,166 · 2020: $919 · 2021: $1,576 · 2022: $1,843 · 2023: $2,421 · 2024: $2,317 · 2025: $1,934.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,323 · Education: $349.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,322.67 |
| Education | $348.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,776.14 | 2019-2025 | |
| Lilly USA, LLC | $1,480.02 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Novartis Pharmaceuticals Corporation | $1,415.76 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $1,312.94 | 2019-2025 | Ilumya, Blu-U, Odomzo |
| Janssen Biotech, INC. | $1,128.25 | 2019-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $986.20 | 2019-2025 | Dupixent, Libtayo |
| Incyte Corporation | $713.23 | 2021-2025 | Opzelura |
| Pfizer INC. | $568.29 | 2019-2025 | |
| Ucb, INC. | $547.34 | 2019-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $446.63 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $402.91 | 2022-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $244.43 | 2019-2025 | Nemluvio, Dysport |
| Leo Pharma INC. | $240.02 | 2021-2025 | Adbry, Anzupgo |
| Prugen, INC. Pharmaceuticals | $120.23 | 2019-2020 | |
| Amgen INC. | $98.76 | 2019-2023 | Otezla |
Show all 36 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrea Mabry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.